Anti-idiotype vaccines for human follicular lymphoma

Bendandi, Maurizio

doi:10.1038/sj.leu.2401861

Cited by 23 publications

(9 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, when it comes to active immunotherapy against lymphoma, the clonal immunoglobulin becomes the target, not the tool. As target, it is considered as a collection of antigens (Bendandi 2000). When considering any immunoglobulin, including the tumor immunoglobulin as an antigen rather than as an antibody, two groups of epitopes are encountered: idiotopes and allotopes.…”

Section: The Tumor Immunoglobulin: the Paradox Of A Useless Antibody mentioning

confidence: 99%

“…They are recognized as foreign by a recipient because of their presence in the immunoglobulin of the donor but not of the recipient. The differences between donor and recipient allotopes are of no functional significance (Bendandi 2000). In contrast, idiotopes are located in the hypervariable regions of the immunoglobulin variable domain, and are recognized as foreign because they do not induce self tolerance, since their small quantity present in the body is insufficient to induce self-tolerance.…”

Section: The Tumor Immunoglobulin: the Paradox Of A Useless Antibody mentioning

confidence: 99%

“…In contrast, idiotopes are located in the hypervariable regions of the immunoglobulin variable domain, and are recognized as foreign because they do not induce self tolerance, since their small quantity present in the body is insufficient to induce self-tolerance. However, the differences between donor and recipient idiotopes may be functionally relevant in the context of B cell function regulation (Bendandi 2000). It is also important to remember that idiotopes and the complementarity-determining regions (CDRs), the most hypervariable portions of the immunoglobulin's variable regions, do not overlap and are not synonymous.…”

Section: The Tumor Immunoglobulin: the Paradox Of A Useless Antibody mentioning

confidence: 99%

“…Inherently, the idiotype is a B-cell clone-specific antigen, which in a malignant clone becomes a tumor-specific antigen (Bendandi 2000).…”

Section: The Tumor Immunoglobulin: the Paradox Of A Useless Antibody mentioning

confidence: 99%

See 3 more Smart Citations

Idiotypic Vaccination: Still a Unique form of Cancer Immunotherapy for Follicular Lymphoma after 20 Years

Inogés¹,

Cerio²,

Villanueva³

et al. 2013

ACRT

View full text Add to dashboard Cite

Idiotypic vaccination for folicular lymphoma induces a tumor-specific immune response which may kill tumor cells in vivo and prevent tumor relapse in patients. However, being based on a personalized vaccine against a person's own tumor, large scale randomized studies have produced contradictory results. The objective of this review is to define what an idiotype is and to outline the major results of twenty years of clinical research on idiotypic vaccination. We first identified the major proofs of principle obtained by its use between 1992 and 2006, focusing on both our and others' contributions. Then, we analyzed the results of randomized clinical trials, which have become available ove the last five years, and provided some of our most recent and original data.A combination of immunological methods should be employed for proper interpretation of immune response following idiotypic vaccination. We describe some of the methods used to measure immune responses and identify tumor idiotype sequences. Some of the older methods (e.g. ELISA) may, in some instances, be misleading, and should be validated using different methods (e.g. flow cytometry). Moreover, patients who relapse years after the end of the vaccination schedule, may have undergone changes in tumor idiotype tumor idiotypes that have undergone substantial changes and is advisable to test the tumor clone at relapse to ascertain it.While idiotypic vaccination has provided proof-of-principle of effectiveness, the data necessary for regulatory approval has yet to be generated. Therefore, better designed, confirmatory clinical trials of idiotypic vaccination are necessary.

show abstract

Section: The Tumor Immunoglobulin: the Paradox Of A Useless Antibody mentioning

confidence: 99%

Section: The Tumor Immunoglobulin: the Paradox Of A Useless Antibody mentioning

confidence: 99%

Section: The Tumor Immunoglobulin: the Paradox Of A Useless Antibody mentioning

confidence: 99%

“…Inherently, the idiotype is a B-cell clone-specific antigen, which in a malignant clone becomes a tumor-specific antigen (Bendandi 2000).…”

Section: The Tumor Immunoglobulin: the Paradox Of A Useless Antibody mentioning

confidence: 99%

See 2 more Smart Citations

Idiotypic Vaccination: Still a Unique form of Cancer Immunotherapy for Follicular Lymphoma after 20 Years

Inogés¹,

Cerio²,

Villanueva³

et al. 2013

ACRT

View full text Add to dashboard Cite

show abstract

“…Autologous myeloma cells can be recognized in a HLA class I-restricted fashion as targets of an idiotype-specific T cell response [79,80]. Idiotype vaccination for multiple myeloma using DCs after autologous peripheral blood progenitor cell transplantation results in the induction of idiotype-specific cellular responses in patients who are in complete remission [81 -83].…”

Section: Dendritic Cellsmentioning

confidence: 99%

Cellular Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation: Experimental Strategies and Clinical Experiences

Abken

Hombach²,

Reinhard³

et al. 2003

Leukemia & Lymphoma

View full text Add to dashboard Cite

Recurrence of disease after autologous hematopoietic stem cell transplantation is at least partly due to contamination of the reinfused transplant with tumor cells, thereby limiting the clinical outcome after transplantation. On the other hand, immunological effector cells are capable of purging bone marrow transplants in vitro and of destroying disseminated tumor cells in vivo. Cellular immunotherapy subsequent to autologous stem cell transplantation is therefore expected to have a major impact on recurrence rates of the disease. In this review, we present various strategies utilizing immunologic effector cells for elimination of disseminated tumor cells and discuss the advantages and limitations of cellular immunotherapy after autologous hematopoietic stem cell transplantation.

show abstract

Current Awareness

2001

Hematological Oncology

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of hematological oncology. Each bibliography is divided into 14 sections: 1 Books, Reviews & Symposia; 2 General; Leukemias: 3 Lymphoblastic; 4 Myeloid & Myelodysplastic Syndromes; 5 Chronic; 6 Others; Lymphomas: 7 Hodgkin's; 8 Non‐Hodgkin's; 9 Plasmacytomas/Multiple Myelomas; 10 Others; 11 Bone Marrow Transplantation; 12 Cytokines; 13 Diagnosis; 14 Cytogenetics. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Anti-idiotype vaccines for human follicular lymphoma

Cited by 23 publications

References 62 publications

Idiotypic Vaccination: Still a Unique form of Cancer Immunotherapy for Follicular Lymphoma after 20 Years

Idiotypic Vaccination: Still a Unique form of Cancer Immunotherapy for Follicular Lymphoma after 20 Years

Cellular Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation: Experimental Strategies and Clinical Experiences

Current Awareness

Contact Info

Product

Resources

About